External validation of the updated international IgA nephropathy prediction tool in a Chinese population.

ABSTRACT:

Objective

The updated post-biopsy International IgA Nephropathy (IgAN) Prediction Tool (IIgAN-PT) requires validation in diverse clinical settings. We evaluated its performance in a Chinese cohort characterized by severe pathology and aggressive immunosuppression therapy.

Methods

Patients with biopsy-confirmed IgAN from two medical centers in China were included. We calculated the predicted risk for each patient. The primary outcome was the first occurrence of end-stage kidney disease(ESKD, eGFR < 15 ml/min/1.73 m², dialysis or transplantation) or a permanent decline in estimated glomerular filtration rate to less than 50% of the baseline time value at one year after kidney biopsy. Model performance was assessed by discrimination, calibration, and reclassification

SUBMITTER: Du X 

PROVIDER: S-EPMC12849634 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature